Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Isis Gear Up For Long-awaited Kynamro Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.

Advertisement

Related Content

Isis Preps To Advance Two Drugs To Phase III In Rare Diseases
Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos
Gene Signal Will Expand Antisense Ophthalmic Studies With New Funds
Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro
Disease Severity Underlies Advisory Committee Support For Kynamro
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel